Neovii supports research and development activities in the fields of solid organ transplantation, stem cell transplantation and immune and hemato-oncological disorders.

Currently, Grafalon® is being investigated in a clinical study in the United States for the prevention of moderate to severe chronic GVHD.

Neovii actively seeks in-licensing and acquisitions opportunities. We are looking to expand our portfolio of products with novel life-transforming therapies that address severe unmet medical needs in particular in the areas of transplantation, hemato-oncology and immune disorders.

If you are interested in exploring potential collaborative opportunities with us, please contact us.